Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (4): 390-396.doi: 10.12092/j.issn.1009-2501.2022.04.006

Previous Articles     Next Articles

Research progress of β2 microglobulin

ZHANG Xiaoyi1, KUAI Zheng1, ZOU Yunzeng2   

  1. 1 Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 2 Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China
  • Online:2022-04-26 Published:2022-05-17

Abstract: β2 microglobulin (β2-MG) is a key component I molecule of the major histocompatibility complex class that assists in the cytotoxic T lymphocyte (CTL) immune response. Serum β2-MG content is dynamically correlated with many diseases. Most studies on β2-MG mainly focus on the pathogenesis of kidney disease, tumor and amyloid fibrils. In recent years, some studies have found that β2-MG is also involved in the adverse prognosis of cardiovascular system, cognitive impairment of aging and antibacterial effects. This paper summarized the domestic and foreign studies on β2-MG in recent years, and proposed the possible role of β2-MG in multi-system human body and its potential application prospect of drug molecular targeting.

Key words: β2 microglobulin, cardiovascular system, senium

CLC Number: